A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters

Autor: Frantz, Phanramphoei N., Barinov, Aleksandr, Ruffié, Claude, Combredet, Chantal, Najburg, Valérie, de Melo, Guilherme Dias, Larrous, Florence, Kergoat, Lauriane, Teeravechyan, Samaporn, Jongkaewwattana, Anan, Billon-Denis, Emmanuelle, Tournier, Jean-Nicolas, Prot, Matthieu, Levillayer, Laurine, Conquet, Laurine, Montagutelli, Xavier, Tichit, Magali, Hardy, David, Fernandes, Priyanka, Strick-Marchand, Hélène, Di Santo, James, Simon-Lorière, Etienne, Bourhy, Hervé, Tangy, Frédéric
Přispěvatelé: Laboratoire d’innovation : vaccins – Innovation lab : vaccines, Institut Pasteur [Paris], Université de Paris (UP), National Center for Genetic Engineering and Biotechnology [Thailand] (BIOTEC), National Science and Technology Development Agency [Bangkok] (NSTDA), VIROxIS [Villejuif], Institut Gustave Roussy (IGR), Lyssavirus, épidémiologie et neuropathologie - Lyssavirus Epidemiology and Neuropathology, Institut de Recherche Biomédicale des Armées (IRBA), Génomique évolutive des virus à ARN - Evolutionary genomics of RNA viruses, Génétique de la souris - Mouse Genetics, Neuropathologie expérimentale / Experimental neuropathology, Institut Pasteur [Paris]-Université de Paris (UP), Immunité Innée - Innate Immunity, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Funding for 'Outbreak Response to Novel Coronavirus (COVID-19): Development of a vaccine against novel coronavirus SARS-CoV-2 using the clinical Phase III measles vector technology' project was provided by the Coalition for Epidemic Preparedness Innovations (CEPI). The development of the mouse-adapted MacO3 virus was funded by the ANR-20-COVI-0028-01 grant program. P.N.F. was supported by the ANR-18-CE17-0004-01 programme, Recherche translationnelle en santé. Part of this work was supported by Institut Pasteur TASK FORCE SARS COV2 (NicoSARS and NeuroCovid projects)., We thank Anastassia Komarova, Vincent Enouf and Sylvie Van Der Werf from the RNA Viruses Molecular Genetics Unit of Institut Pasteur for helpful discussions and SARS-Cov-2 virus information. We thank Maud Vanpeene and Vincent Enouf from the Mutualized Platform of Microbiology, Pasteur International Bioresources Network for viral sequencing. We thank Victoire Perraud and Simon Bonas from the Lyssavirus Epidemiology and Neuropathology Unit for their help with animal experiments and RNA extraction. We thank Audrey Ferrier, Annabelle Garnier, and Laurence Cheutin from the Armed Forces Biomedical Research Institute (IRBA) for handling the serums cohort from SARS-Cov-2 convalescent patients., ANR-20-COVI-0028,HuMoCID,Développement de modèles murins de COVID-19(2020), ANR-18-CE17-0004,ComboVaxEm,Des vaccins combinés contre les infections virales émergentes(2018), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Université Paris Cité (UPCité), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hardy, David, Développement de modèles murins de COVID-19 - - HuMoCID2020 - ANR-20-COVI-0028 - COVID-19 - VALID, APPEL À PROJETS GÉNÉRIQUE 2018 - Des vaccins combinés contre les infections virales émergentes - - ComboVaxEm2018 - ANR-18-CE17-0004 - AAPG2018 - VALID, Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications
Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.6277. ⟨10.1038/s41467-021-26506-2⟩
Nature Communications, 2021, 12 (1), pp.6277. ⟨10.1038/s41467-021-26506-2⟩
ISSN: 2041-1723
DOI: 10.1038/s41467-021-26506-2⟩
Popis: Several COVID-19 vaccines have now been deployed to tackle the SARS-CoV-2 pandemic, most of them based on messenger RNA or adenovirus vectors.The duration of protection afforded by these vaccines is unknown, as well as their capacity to protect from emerging new variants. To provide sufficient coverage for the world population, additional strategies need to be tested. The live pediatric measles vaccine (MV) is an attractive approach, given its extensive safety and efficacy history, along with its established large-scale manufacturing capacity. We develop an MV-based SARS-CoV-2 vaccine expressing the prefusion-stabilized, membrane-anchored full-length S antigen, which proves to be efficient at eliciting strong Th1-dominant T-cell responses and high neutralizing antibody titers. In both mouse and golden Syrian hamster models, these responses protect the animals from intranasal infectious challenge. Additionally, the elicited antibodies efficiently neutralize in vitro the three currently circulating variants of SARS-CoV-2.
Here the authors generate a measles virus-based vaccine expressing SARSCoV-2 spike protein and show immunogenicity and protection in mice and hamsters, including neutralization of circulating variants of concerns in vitro.
Databáze: OpenAIRE
Externí odkaz: